Ixempra (ixabepilone) plus Xeloda (capecitabine) doubled the progression-free survival (PFS) rate for women with triple-negative breast cancer (TNBC), according to research that analyzed the results of five Phase II and two Phase III studies. In all, 2,261 were evaluated, with 24.5 percent, or 556 of these having TNBC—cancers that are negative for estrogen, progesterone and Her2 (Human Epidermal growth factor Receptor 2).
In an overall analysis of all trials, women with TNBC who used both Ixempra and Xeloda saw an overall response rate (ORR) of 23 to 31 percent, with results varying from study to study.
The pathologic complete response for TNBC women on Ixempra was 26 percent, versus 15 percent in the non-triple-negative population.
Patients with metastatic breast cancer in the studies had a variety of treatments before Ixempra therapy, so their ORR varied significantly, from 6 to 55 percent; rates, though, were comparable to those in patients with non-triple-negative.
Progression-free survival (PFS) was significantly longer for triple-negative patients treated with Ixempra and Xeloda (4.2 months) compared with treatment with Xeloda alone (1.7 months).